Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-10-14

Butterfly Network, Inc.

Butterfly sells handheld ultrasound devices, cloud workflow software, and partner-facing developer and licensing tools for clinicians, health systems, medical schools, and new ultrasound-enabled products.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof of platform beyond probe sales

The upside case now rests on turning handheld ultrasound into a governed workflow and partner-distribution surface. Recent Embedded and education wins help, but the next real test is whether commercialization broadens faster than cash burn and incumbent bundling pressure.

Analysis

Thesis

Butterfly can still create a 2x-plus equity outcome by 2031 if it turns a differentiated handheld ultrasound product into a governed workflow and partner-distribution platform, with AI lowering the skill barrier to scanning and lifting the value of its probe, cloud, and Embedded surfaces together.

Last Economy Alignment

AI should expand who can safely use ultrasound, and Butterfly owns the hardware plus regulated workflow layer where value capture is less exposed to pure software deflation. The upside depends on making Garden and Embedded durable revenue engines, not just feature demos.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

The return case comes from Butterfly becoming a better business, not just a bigger device vendor. If more of each deployment turns into recurring workflow, education, and partner revenue, investors can accept a large revenue base with healthier mix quality and lower cash-burn risk. That supports meaningful upside even if the future revenue multiple is below today’s level.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is conversion, not invention. Butterfly already has a real product and improving margins, but the 2031 upside requires software, education, and Embedded revenue to become repeatable before valuation enthusiasm outruns evidence.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On October 1, 2026, Mendaera became the first Butterfly Embedded partner with a commercially available Butterfly-compatible system, improving proof that partner revenue can leave pilot mode.
On October 6, 2026, Butterfly added another multi-year Embedded agreement with Bridge Neurotech, expanding the option set for milestone and hardware revenue outside core imaging.
On October 8, 2026, Butterfly scheduled Q3 2026 results for October 29, 2026, fixing the next hard checkpoint for cash use, margin mix, and commercialization progress.
On October 13, 2026, the VCOM alliance deepened the education flywheel by tying probe deployment to longitudinal cloud usage beyond graduation.

Thesis update

No material thesis change. The last 10 days added evidence that Embedded and education loops are real, but not enough yet to prove broad commercial repeatability.

Forecast update

Slightly better asymmetry comes from a lower current enterprise value and the first commercial Embedded proof point, but the core rating still waits on diversification beyond a few visible relationships.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.45

They control the probe, the clinical workflow around it, and a small but growing developer surface, so AI can make ultrasound useful to many more clinicians instead of fewer specialists. The risk is that bigger imaging vendors bundle similar features and Butterfly never proves that software and partner revenue matter as much as the hardware.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$11.40

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research